Abstract
Background: Long noncoding RNA (lncRNA) fetal-lethal non-coding developmental regulatory RNA (FENDRR), a newly known lncRNA, has been reported to be abnormally expressed in diverse tumors. This review is focused on clarifying the mechanism of FENDRR to regulate the biological process of tumors, affirming its value as a target for tumor therapy.
Methods: The pathophysiological mechanism of FENDRR acting on tumors has been analyzed and summarized by reviewing PubMed.
Results: The expression of lncRNA FENDRR is abnormally altered in clinical cancers, promoting the malignant transformation of a variety of tumors, including colon cancer, cervical cancer, hepatocellular carcinoma, prostate cancer, Malignant melanoma, lung cancer, osteosarcoma, breast cancer, etc. Cellular processions, including proliferation, invasion, apoptosis and migration affected by FENDRR, have been revealed.
Conclusion: Specific evidences for the involvement of LncRNA FENDRR in cancer regulatory processes suggest that FENDRR has the potential to be a biomarker or clinical therapeutic target for malignant tumors.
Keywords: Long non-coding RNA, FENDRR, cancer, biomarkers, therapeutic targets, clinical prognosis.
Current Pharmaceutical Design
Title:The Therapeutic Value and Molecular Mechanisms of lncRNA FENDRR in Human Cancer
Volume: 27 Issue: 39
Author(s): Wen Xu, Bei Wang, Yuxuan Cai, Jinlan Chen, Enqing Meng, Chong Guo, Gang Zhou*Chengfu Yuan*
Affiliation:
- College of Traditional Chinese Medicine, China Three Gorges University, Yichang 443002,China
- College of Medical Science, China Three Gorges University, Yichang 443002,China
Keywords: Long non-coding RNA, FENDRR, cancer, biomarkers, therapeutic targets, clinical prognosis.
Abstract:
Background: Long noncoding RNA (lncRNA) fetal-lethal non-coding developmental regulatory RNA (FENDRR), a newly known lncRNA, has been reported to be abnormally expressed in diverse tumors. This review is focused on clarifying the mechanism of FENDRR to regulate the biological process of tumors, affirming its value as a target for tumor therapy.
Methods: The pathophysiological mechanism of FENDRR acting on tumors has been analyzed and summarized by reviewing PubMed.
Results: The expression of lncRNA FENDRR is abnormally altered in clinical cancers, promoting the malignant transformation of a variety of tumors, including colon cancer, cervical cancer, hepatocellular carcinoma, prostate cancer, Malignant melanoma, lung cancer, osteosarcoma, breast cancer, etc. Cellular processions, including proliferation, invasion, apoptosis and migration affected by FENDRR, have been revealed.
Conclusion: Specific evidences for the involvement of LncRNA FENDRR in cancer regulatory processes suggest that FENDRR has the potential to be a biomarker or clinical therapeutic target for malignant tumors.
Export Options
About this article
Cite this article as:
Xu Wen , Wang Bei , Cai Yuxuan , Chen Jinlan, Meng Enqing, Guo Chong , Zhou Gang *, Yuan Chengfu *, The Therapeutic Value and Molecular Mechanisms of lncRNA FENDRR in Human Cancer, Current Pharmaceutical Design 2021; 27 (39) . https://dx.doi.org/10.2174/1381612827666210820094702
DOI https://dx.doi.org/10.2174/1381612827666210820094702 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Marine Peptides and Related Compounds in Clinical Trial+
Anti-Cancer Agents in Medicinal Chemistry Imaging Tumor Metastases with Molecular Probes
Current Pharmaceutical Design Genitourinary Tract Tumors in Children: An Update
Current Pediatric Reviews Carbohydrates: Potential Sweet Tools Against Cancer
Current Medicinal Chemistry Inflammation and Anemia
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry An Overview on the Development of New Potentially Active Camptothecin Analogs Against Cancer
Mini-Reviews in Medicinal Chemistry Development of Drug Targeting and Delivery in Cervical Cancer
Current Cancer Drug Targets Genetic and Modifying Factors that Determine the Risk of Brain Tumors
Central Nervous System Agents in Medicinal Chemistry Characterization of the Lymphotropic Amplicons-6 and Tamplicon-7 Vectors Derived from HHV-6 and HHV-7
Current Gene Therapy Tyrosine Kinase Inhibitors – A Review on Pharmacology, Metabolism and Side Effects
Current Drug Metabolism Epigenetic Modulation Using Small Molecules - Targeting Histone Acetyltransferases in Disease
Current Medicinal Chemistry Cyclooxygenase-2: Potential Role in Regulation of Drug Efflux and Multidrug Resistance Phenotype
Current Pharmaceutical Design Is the Vagina an Adequate Route for the Administration of Hormonal Contraceptives?
Current Drug Metabolism Advances in Research on the Preparation and Biological Activity of Maslinic Acid
Mini-Reviews in Medicinal Chemistry Anti-Cancer Drug Design Using Natural and Synthetic Pharmacophores
Current Organic Chemistry Selected Attributes of Polyphenols in Targeting Oxidative Stress in Cancer
Current Topics in Medicinal Chemistry Radiolabeled Oligonucleotides for Antisense Imaging
Current Organic Synthesis Microneedle Patches as Drug and Vaccine Delivery Platform
Current Medicinal Chemistry Pituitary Adenylate Cyclase Activating Polypeptide: A Potential Neuroprotective Peptide
Current Pharmaceutical Design Editorial Review (Thematic Issue: An Update on Central Sensitivity Syndromes and the Issues of Nosology and Psychobiology)
Current Rheumatology Reviews